PUBLISHER: The Business Research Company | PRODUCT CODE: 1945270
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945270
A heart defect closure device is a medical instrument designed to close abnormal openings or defects in the heart's structure, particularly in the septum, the wall that separates the heart's chambers. These devices are used to treat specific heart conditions, such as atrial septal defects or patent foramen ovale, by sealing the openings in the heart's wall. They are implanted through minimally invasive procedures, offering an effective and less invasive alternative to open-heart surgery for patients with these defects.
The primary types of heart defect closure devices include atrial septal defect (ASD) closure devices, left atrial appendage (LAA) closure devices, patent foramen ovale (PFO) closure devices, patent ductus arteriosus (PDA) closure devices, and ventricular septal defect (VSD) closure devices. An ASD closure device is specifically designed to seal a hole in the wall between the heart's two upper chambers. These devices are constructed from various materials such as nitinol and stainless steel and can be delivered through transcatheter, surgical, and other delivery methods by hospitals, clinics, ambulatory surgical centers, and other healthcare facilities.
Tariffs are impacting the heart defect closure device market by increasing costs for imported nitinol alloys, precision components, and specialized manufacturing equipment. These effects are most pronounced in north america, europe, and asia-pacific, where supply chains are globally integrated. Higher input costs have influenced device pricing and procurement decisions for hospitals and cardiac centers. However, tariffs are also encouraging local manufacturing, regional supplier development, and investment in domestic production capabilities, supporting long-term supply chain resilience.
The heart defect closure device market research report is one of a series of new reports from The Business Research Company that provides heart defect closure device market statistics, including heart defect closure device industry global market size, regional shares, competitors with a heart defect closure device market share, detailed heart defect closure device market segments, market trends and opportunities, and any further data you may need to thrive in the heart defect closure device industry. This heart defect closure device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The heart defect closure device market size has grown rapidly in recent years. It will grow from $1.27 billion in 2025 to $1.45 billion in 2026 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to increasing prevalence of congenital heart defects, advancements in interventional cardiology, growing awareness of septal defect treatments, expansion of cardiac catheterization labs, rising demand for minimally invasive cardiac procedure.
The heart defect closure device market size is expected to see rapid growth in the next few years. It will grow to $2.36 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to growing elderly and pediatric patient population with structural heart defects, rising adoption of transcatheter cardiac interventions, increasing healthcare expenditure on cardiovascular care, expansion of specialized cardiac centers, growing focus on early diagnosis and treatment of heart defects. Major trends in the forecast period include rising adoption of minimally invasive transcatheter closure procedures, growing use of nitinol-based and self-expanding closure devices, increasing preference for device-based alternatives to open-heart surgery, expansion of structural heart disease treatment programs, rising focus on improved safety, efficacy, and long-term outcomes.
The increasing prevalence of congenital heart problems is expected to drive the growth of the heart defect closure device market in the coming years. Congenital heart problems are structural defects in the heart present from birth. The rise in congenital heart issues can be attributed to factors such as genetic predispositions, environmental influences, and maternal health conditions like diabetes, obesity, and exposure to certain medications or infections during pregnancy. Heart defect closure devices provide minimally invasive solutions to treat these conditions by sealing abnormal heart openings, restoring normal blood flow, reducing complications, and enhancing overall cardiac function. For instance, in March 2025, according to the Centers for Disease Control and Prevention, a US-based government agency, nearly 1% of U.S. newborns-approximately 40,000 each year-are born with heart defects, and one in four of these infants requires surgery within the first year. As a result, the growing number of individuals with congenital heart problems is driving the expansion of the heart defect closure device market.
Major companies in the heart defect closure device market are advancing technologies such as device tracking tools to improve procedural accuracy and clinician confidence. A device tracking tool is a system that provides real-time visualization of the position and movement of medical devices during treatment. For instance, in November 2025, Philips, a Netherlands-based health technology company, launched DeviceGuide-an AI-driven tracking solution designed to assist clinicians during complex minimally invasive heart valve repair procedures, particularly for mitral valve regurgitation. Integrated with the EchoNavigator platform, DeviceGuide combines live X-ray and ultrasound imaging to generate a real-time 3D model of the repair device within the beating heart, enhancing visualization, orientation, and procedural precision. Developed in collaboration with Edwards Lifesciences, the system streamlines workflows, improves team coordination, and promotes broader access to advanced cardiac interventions globally.
In February 2023, Boston Scientific Corporation, a US-based medical device manufacturer, acquired a 65% stake in Acotec Scientific Holdings Limited for $0.523 billion. This acquisition enhances Boston Scientific Corporation's position in China and enables the global commercialization of Acotec Scientific Holdings Limited's products. Acotec Scientific Holdings Limited is a China-based medical device company specializing in the interventional treatment of vascular diseases.
Major companies operating in the heart defect closure device market are Abbott Laboratories, Medtronic, W L Gore and Associates, Occlutech, LifeTech Scientific Corporation, Lepu Medical Technology, Meril Life Sciences Pvt Ltd, MicroPort Scientific Corporation, Boston Scientific Corporation, Edwards Lifesciences, Terumo Corporation, Cardia Inc, Coherex Medical Inc, AtriCure Inc, Sahajanand Medical Technologies Limited, Vivasure Medical, Transmural Systems Inc, Cormatrix Cardiovascular Inc, Baylis Medical Company Inc, Biosense Webster Inc, BIOTRONIK SE and Co KG, B Braun
North America was the largest region in the heart defect closure device market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the heart defect closure device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the heart defect closure device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The heart defect closure device market consists of sales of amplatzer septal occluder, gore cardioform septal occluder, and HELEX septal occluder. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Heart Defect Closure Device Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses heart defect closure device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for heart defect closure device ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The heart defect closure device market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.